Axonics (Nasdaq:AXNX) announced today that Dan Dearen, president and CFO, is retiring from his position at the neuromodulation company. Irvine, California-based Axonics tabbed Kari Keese, VP of finance and accounting, to succeed Dearen. Her appointment goes into effect on Oct. 2. “On behalf of the Axonics team and the board of directors, I want to […]
Axonics
Axonics acquires tech to expedite placement of implantable leads in sacral neuromod
Axonics (Nasdaq:AXNX) today announced it acquired lead placement technology from Radian to speed up the placement of implantable leads for sacral neuromodulation. Axonics acquired the assets of Radian from Intermed Labs for an undisclosed amount. The company expects the product to receive FDA clearance and be available on a commercial basis in mid-2024. The acquired technology […]
New medtech to watch for in 2023: boosting health outcomes
As earnings season is upon us, we’re receiving a clearer view of what new medtech could be launching this year in the medical device space. Companies still feel hamstrung by macroeconomic pressures, supply chain issues and more. However, many pointed out that 2023 has plenty to look forward to. Several quarterly reports and earnings calls […]
FDA approves fourth-gen rechargeable sacral neuromod tech from Axonics
Axonics (Nasdaq:AXNX) announced today that the FDA approved its fourth-generation R20 rechargeable sacral neuromodulation system. The implantable system provides therapy for patients suffering from overactive bladder or fecal incontinence. The approval indicates the Axonics R20 for a functional life in the body of at least 20 years. It also reduces the frequency with which a […]
Axonics receives Health Canada approval for rechargeable sacral neuromod
Axonics (Nasdaq:AXNX) announced today that Health Canada approved its fourth-generation rechargeable sacral neuromodulation (SNM) system. Irvine, California-based Axonics’ R20 neurostimulator received labeling for a functional life in the body of at least 20 years. It reduces how frequently a patient must recharge their implanted device to once every six to 10 months. The devices charge […]
Axonics, Outset lead medtech space on Deloitte’s list of fastest growing companies
Deloitte today released its “North America Technology Fast 500” list of growing companies, including a handful of medtech firms. The list, which ranking of the fastest-growing North American companies across a range of sectors, included several “Life Sciences” outfits. Immunology company Vir Biotechnology led the way in first place on the list. Axonics (Nasdaq:AXNX) represented […]
Axonics stock dips after hours despite Street-beating Q3, raised guidance
Axonics (Nasdaq:AXNX) shares took a hit after hours despite third-quarter results that bettered the consensus forecast. Shares of AXNX dipped 7% to $68 apiece after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 0.2%. The Irvine, California-based sacral neuromodulation (SNM) […]
Axonics announces first patient implants in Canada for sacral neuromod system
Axonics (Nasdaq:AXNX) today announced the first patient implants in Canada for its Axonics F15 sacral neuromodulation (SNM) system. Irvine, California-based Axonics designed its new F15 as a long-lived, fully recharge-free SNM system. It received Health Canada approval after FDA approval in March. The company’s U.S. launch took place the following month. According to a news […]
10 big earnings stories from the last quarter: How are medtech stocks doing now?
Economic uncertainty appears to have produced a wide variety of medtech earnings stories during the most recent round of quarterly results. Some medical device companies received massive boosts from their quarterly performance, while others saw their stocks sink amid missed projections and other various issues. The phrase “macroeconomic headwinds” was a common phrase. Medtech faces […]
Axonics expands IP portfolio with new patents
Axonics (Nasdaq:AXNX) announced today that it has been granted eight patents and allowed a further four applications in the past 12 months. Irvine, California-based Axonics eight granted patents and four applications to the U.S. Patent and Trademark Office relate to its portfolio of sacral neuromodulation (SNM) technology. According to a news release, the patents represent […]
Axonics expects 40% revenue growth this year
Axonics (Nasdaq:AXNX) shares are on the rise today on second-quarter results that came in ahead of the consensus forecast amid a successful TV advertising campaign. The Irvine, California–based sacral neuromodulation technology developer posted losses of $34.1 million, or 47¢ per share, on sales of $69 million for the three months ended June 30, 2022, for […]
